Primary Liver Cancer Clinical Trial
| Verified date | December 2014 |
| Source | Tel-Aviv Sourasky Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Israel: Ethics Commission |
| Study type | Interventional |
Supplementation of BCAA found to reduce the risk of developing liver cancer, but the affect
of BCAA on existing liver cancer is unknown.
The participants (post curative intent surgery) will be supplemented with either
BCAA/non-BCAA-enriched protein supplement. The intervantion will go on for 2 years or until
a new liver tumor is found.
| Status | Not yet recruiting |
| Enrollment | 60 |
| Est. completion date | |
| Est. primary completion date | December 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - diagnosed primary liver cancer - viral or Nonalcoholic Steatohepatitis Cirrhosis - Cirrhosis rated Child-Pugh A - liver cancer rated Barcelona Clinic Liver Cancer (BCLC) A Exclusion Criteria: - Age (over 65) - liver condition rated Child-Pugh B/C - GI/Absorption issues - patients given a treatment before surgery |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)
| Country | Name | City | State |
|---|---|---|---|
| Israel | Clinical Nutrition Unit, Sourasky Medical Center | Tel Aviv |
| Lead Sponsor | Collaborator |
|---|---|
| Tel-Aviv Sourasky Medical Center |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | time until a new liver tumor is found | 2 years | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03161925 -
Chinese Liver Cancer Clinical Survey
|
N/A | |
| Completed |
NCT00261378 -
Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation
|
Phase 2 | |
| Enrolling by invitation |
NCT05609448 -
MRI-guided Holmium-166 Radioembolization
|
N/A | |
| Recruiting |
NCT05714124 -
Liver Embolization Approaches for Tumor Management
|
||
| Not yet recruiting |
NCT05353894 -
Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT03518632 -
Preoperative Physical Activity Intervention in Patients Before Planned Liver Resection for Cancer (APACHE)
|
N/A | |
| Terminated |
NCT00003530 -
Antineoplaston Therapy in Treating Patients With Primary Liver Cancer
|
Phase 2 | |
| Recruiting |
NCT04806464 -
Clinical Study of VG161 in Subjects With Advanced Primary Liver Cancer
|
Phase 1 | |
| Recruiting |
NCT06342414 -
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
|
||
| Completed |
NCT01116804 -
Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)
|
Phase 1 | |
| Recruiting |
NCT03067493 -
RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial
|
Phase 2 | |
| Completed |
NCT05183776 -
Clinical Validation of a Fractional Administration Device for Holmium-166 SIRT
|
N/A | |
| Not yet recruiting |
NCT06430983 -
Recurrent Liver Cancer: Reconceptualization and Reevaluation
|
||
| Recruiting |
NCT05677724 -
Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment
|
||
| Not yet recruiting |
NCT03178929 -
Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma
|
N/A | |
| Recruiting |
NCT05267080 -
Registry on Percutaneous Electrochemotherapy
|
||
| Completed |
NCT01640522 -
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
|
N/A | |
| Completed |
NCT00408122 -
Evaluation of Preoperative Investigations in Patients With Liver Cancer
|
N/A | |
| Recruiting |
NCT03297255 -
Primary Liver Cancer Cohort of South China
|
N/A | |
| Recruiting |
NCT06325267 -
Clinical Characteristics of Primary Liver Cancer
|